Gridai Technologies Corp. annual report, FY2023

Business context and reporting period

Filing identity: The supplied filing is First Wave BioPharma, Inc.’s Form 10-K, not a filing for Gridai Technologies Corp. It covers the fiscal year ended December 31, 2023; the financial statements do not include the March 2024 ImmunogenX merger.

First Wave is a clinical-stage biotechnology company developing gastrointestinal therapies. Its programs include latiglutenase for celiac disease, Adrulipase for exocrine pancreatic insufficiency, Capeserod for gastrointestinal indications, and Niclosamide, which the company proposed to sell. It reported no product revenue and no approved products.

Financial results and liquidity

At December 31, 2023, working capital was approximately $1.82 million, total liabilities were $3.28 million, and stockholders’ equity was $3.60 million. The balance sheet included a $613,000 note payable, principally insurance-premium financing. The filing reports no meaningful operating margins because the company had no revenue. Preferred-stock dividends of approximately $308,000 accrued in 2023.

Operating expenses rose in aggregate to $15.77 million from $12.68 million, and net loss increased 8%. The comparison is affected by a $8.09 million research-and-development recovery recorded in 2022 related to acquired intellectual property; excluding that recovery, reported R&D expense declined in 2023. Lower 2023 cash used in operations also reflected changes in working capital and the absence of the prior-year acquisition-related payable reduction. Financing activities provided $15.23 million in 2023, mainly from warrant exercises and securities offerings.

Material developments and outlook

• Going concern: The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management said additional financing is needed; the statements contain no adjustments for the outcome of this uncertainty.
• ImmunogenX merger: Closed March 13, 2024, after year-end. Consideration included 36,830 common shares and 11,777.418 Series G preferred shares, each initially convertible into 1,000 common shares subject to conditions and stockholder approval. The acquisition accounting was incomplete when the 10-K was filed. The merger adds latiglutenase and CypCel, but creates significant potential dilution.
• Post-year-end financing: A March 2024 registered direct offering raised approximately $4.0 million gross before fees and included warrants for up to 525,625 shares. This does not, by itself, resolve the disclosed funding and going-concern uncertainty.
• Debt assumed with ImmunogenX: The amended revolving facility has a stated commitment of $8.21 million, bears interest at prime plus 6%, and matures September 13, 2025; further borrowing is generally restricted. It is secured by substantially all ImmunogenX assets and includes pledged equity and a lender call right. Two $500,000 secured shareholder notes also mature in October 2025. These are post-year-end obligations; the filing does not provide a clear amount outstanding under the facility at the 10-K date.
• Clinical programs: Latiglutenase was expected to enter two Phase 3 trials in the first half of 2025. Adrulipase’s July 2023 Phase 2b results suggested the primary efficacy endpoint was likely not met, despite tolerability; management planned an FDA Type C meeting in 2024. Capeserod was licensed from Sanofi, with a $500,000 upfront payment, potential development and regulatory milestones up to $46 million, commercial milestones up to $235 million, and royalties; management planned further regulatory discussions and clinical development. Sanofi has a right of first refusal.
• Niclosamide: The company entered a non-binding LOI for a proposed sale with a low seven-figure upfront payment plus potential milestones and royalties. The transaction remained contingent on diligence, definitive agreements, financing, and approvals. The filing gives inconsistent expected closing timing—first half in the MD&A and second half elsewhere—and no sale should be assumed completed. The company said it was no longer actively pursuing several Niclosamide clinical programs.
• Listing, dilution, and other matters: The company effected a 1-for-20 reverse stock split in December 2023. Nasdaq had issued a letter of reprimand relating to a prior offering’s shareholder-approval violation; the company had regained minimum-bid-price compliance, but the filing said it was awaiting a determination on the minimum-equity requirement. A Delaware advancement-fee case brought by a former director was decided in the company’s favor in September 2023, and his request for reargument was denied.

Management expects continued losses and significant development spending, and states that additional equity, debt, collaborations, or other funding will be needed. Risks include clinical and regulatory failure, dependence on contract manufacturers and research organizations, competition, financing constraints, preferred-stock redemption or conversion, potential dilution, debt default and collateral enforcement, and Nasdaq listing compliance. No numerical revenue or earnings guidance is provided.

Most important facts for investors to verify

• Current cash, operating cash burn, financing availability, and management’s updated assessment of the going-concern risk.
• Outstanding balance, payment terms, collateral, covenants, and default status of the ImmunogenX facility and shareholder notes.
• Terms and approval status of Series G conversion and any required share authorization; resulting dilution and potential cash-redemption obligations.
• Definitive status, consideration, and closing timing of the Niclosamide sale; resolve the inconsistent timing disclosed in the 10-K.
• FDA feedback and development plans following the Adrulipase study and for latiglutenase and Capeserod, including funding and trial timing.
• Nasdaq’s determination on continued-listing requirements and the effects of outstanding warrants, options, and other convertible securities.